X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
oncology (29) 29
female (28) 28
middle aged (28) 28
head and neck neoplasms - drug therapy (27) 27
male (26) 26
chemotherapy (23) 23
carcinoma, squamous cell - drug therapy (22) 22
aged (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
cancer (21) 21
head and neck neoplasms - radiotherapy (20) 20
carcinoma, squamous cell - radiotherapy (18) 18
combined modality therapy (18) 18
radiotherapy (18) 18
cisplatin - administration & dosage (16) 16
adult (14) 14
fluorouracil - administration & dosage (14) 14
head and neck cancer (14) 14
squamous cell carcinoma (12) 12
head and neck neoplasms - therapy (11) 11
index medicus (11) 11
neoplasm staging (10) 10
treatment outcome (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
chemoradiotherapy (9) 9
head and neck neoplasms - pathology (9) 9
radiation-therapy (9) 9
carcinoma, squamous cell - pathology (8) 8
squamous-cell carcinoma (8) 8
carcinoma, squamous cell - therapy (7) 7
cisplatin (7) 7
radiotherapy dosage (7) 7
survival analysis (7) 7
carcinoma, squamous cell - mortality (6) 6
care and treatment (6) 6
chemotherapy, adjuvant (6) 6
drug administration schedule (6) 6
head and neck neoplasms - mortality (6) 6
neoplasm recurrence, local - drug therapy (6) 6
radiation (6) 6
randomized trial (6) 6
antineoplastic agents - therapeutic use (5) 5
cetuximab (5) 5
head and neck (5) 5
hematology, oncology and palliative medicine (5) 5
remission induction (5) 5
survival (5) 5
therapy (5) 5
aged, 80 and over (4) 4
cancer-treatment (4) 4
clinical trials (4) 4
deoxycytidine - analogs & derivatives (4) 4
disease progression (4) 4
fluorouracil (4) 4
fluorouracil - therapeutic use (4) 4
gemcitabine (4) 4
head and neck carcinoma (4) 4
induction chemotherapy (4) 4
medicine, general & internal (4) 4
neck (4) 4
platinum (4) 4
prognosis (4) 4
radiotherapy, adjuvant (4) 4
survival rate (4) 4
thrombocytopenia - chemically induced (4) 4
trial (4) 4
5-fluorouracil (3) 3
abridged index medicus (3) 3
accelerated radiotherapy (3) 3
anemia - chemically induced (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast cancer (3) 3
carcinoma (3) 3
carcinoma, squamous cell - secondary (3) 3
chemo-radiotherapy (3) 3
cisplatin - therapeutic use (3) 3
deoxycytidine - administration & dosage (3) 3
disease-free survival (3) 3
irradiation (3) 3
larynx (3) 3
local-control (3) 3
locally advanced head (3) 3
management (3) 3
medical research (3) 3
oncology group rtog (3) 3
organ preservation (3) 3
otorhinolaryngology (3) 3
patients (3) 3
radiation therapy (3) 3
radiation-sensitizing agents - therapeutic use (3) 3
radiology, nuclear medicine & medical imaging (3) 3
radiotherapy - adverse effects (3) 3
randomization (3) 3
randomized clinical trial (3) 3
randomized controlled trials as topic (3) 3
recurrent (3) 3
safety (3) 3
skin (3) 3
skin toxicity (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 11, pp. 1116 - 1127
Journal Article
by Burtness, Barbara and Harrington, Kevin J and Harrington, Kevin and Greil, Richard and Soulières, Denis and Tahara, Makoto and de Castro, Gilberto and Psyrri, Amanda and Basté, Neus and Neupane, Prakash and Bratland, Åse and Bratland, Aase and Fuereder, Thorsten and Hughes, Brett G M and Hughes, Brett and Mesía, Ricard and Ngamphaiboon, Nuttapong and Rordorf, Tamara and Wan Ishak, Wan Zamaniah and Hong, Ruey-Long and González Mendoza, René and Roy, Ananya and Zhang, Yayan and Gumuscu, Burak and Cheng, Jonathan D and Jin, Fan and Rischin, Danny and Lerzo, Guillermo and Tatangelo, Marcelo and Varela, Mirta and Zarba, Juan Jose and Boyer, Michael and Gan, Hui and Gao, Bo and Mallesara, Girish and Taylor, Anne and Burian, Martin and Barrios, Carlos Henrique and de Castro Junior, Dalvaro Oliveira and Castro, Gilberto and Franke, Fabio Andre and Girotto, Gustavo and Lima, Iane Pinto Figueiredo and Nicolau, Ulisses Ribaldo and Pinto, Gustavo Dix Junqueira and Santos, Lucas and Victorino, Ana-Paula and Chua, Neil and Couture, Felix and Gregg, Richard and Hansen, Aaron and Hilton, John and McCarthy, Joy and Soulieres, Denis and Ascui, Rodrigo and Gonzalez, Pablo and Villanueva, Luis and Torregroza, Marco and Zambrano, Angela and Holeckova, Petra and Kral, Zdenek and Melichar, Bohuslav and Prausova, Jana and Vosmik, Milan and Andersen, Maria and Gyldenkerne, Niels and Jurgens, Hannes and Putnik, Kadri and Reinikainen, Petri and Gruenwald, Viktor and Laban, Simon and Aravantinos, Gerasimos and Boukovinas, Ioannis and Georgoulias, Vassilis and Kwong, Dora and Al-Farhat, Yousuf and Csoszi, Tibor and Erfan, Jozsef and Horvai, Geza and Landherr, Laszlo and Remenar, Eva and Ruzsa, Agnes and Szota, Judit and Billan, Salem and Gluck, Iris and Gutfeld, Orit and Popovtzer, Aron and Benasso, Marco and Bui, Simona and Ferrari, Vittorio and Licitra, Lisa and Nole, Franco and Fujii, Takashi and Fujimoto, Yasushi and Hanai, Nobuhiro and Hara, Hiroki and Matsumoto, Koji and Mitsugi, Kenji and Monden, Nobuya and Nakayama, Masahiro and ...
The Lancet, ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1915 - 1928
Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved... 
Chemotherapy | Squamous cell carcinoma | Metastasis | Analysis | Cancer | Medical research | 5-Fluorouracil | Mortality | Oncology | Survival | Metastases | Population (statistical) | Pembrolizumab | Hypotheses | Randomization | Motivation | Platinum | Cell death | PD-L1 protein | Population | Head and neck cancer | Ligands | Larynx | Safety | Apoptosis
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 9/2012, Volume 20, Issue 9, pp. 2141 - 2147
Journal Article
Journal Article
Tumori, ISSN 0300-8916, 07/2008, Volume 94, Issue 4, pp. 26 - 29
Journal Article
Journal Article
Tumori, 08/2019, p. 300891619868289
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease often presenting at an already advanced stage. Cisplatin chemoradiotherapy is the... 
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 71, pp. 34 - 42
Journal Article